Company Information

  

Address: 50 TICE BOULEVARD, SUITE 315  
City: WOODCLIFF LAKE 
State: NJ 
Zip Code: 07677 
Telephone: 201-326-5300 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company registered at and with principal offices at 50 Tice Boulevard, Suite 315, Woodcliff Lake, New Jersey 07677. On November 16, 2016, we purchased all of the outstanding capital stock of Arsia Therapeutics, Inc. ("Arsia"), and subsequently changed its name to Eagle Biologics, Inc. ("Eagle Biologics"). Business Our business model is to develop proprietary innovations to FDA-approved, injectable drugs, that offer commercial and/or functional advantages to currently available alternatives. We have historically been, and will continue to primarily be, focused on developing and commercializing injectable drugs, primarily in the critical care and oncology areas, using the United States Food and Drug Administration ("FDA")'s 505(b)(2) New Drug Application ("NDA") regulatory pathway.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/20182.02NA26.08
12/20173.27NA16.34
09/20176.18NA9.65
06/20175.92NA13.33
03/20176.44NA12.88
12/20164.96NA16.00
09/20161.54NA45.45
06/20160.17NA228.18

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity0.34Total Liab/Total Assets0.34
Net Inc/Total Assets0.19Total Liab/Inv Cap0.42
Net Inc/Inv Cap0.24Total Liab/Comm Equity0.59
Pretax Inc/Net Sales0.31Interest Coverage Ratio65.21
Net Inc/Net Sales0.22Curr Debt/Equity0.03
Cash Flow/Net Sales0.25LTD/Equity0.24
SG&A/NetSales0.27Total Debt/Equity0.27
Asset Utilization   Liquidity  
Net Receivables Turnover4.93Quick Ratio3.88
Inventory Turnover14.56Current Ratio3.99
Inventory Day Sales0.03Net Rec/Curr Assets0.29
Net Sales/Work Cap1.67Inv/Curr Assets0.03
Net Sales/PP&E34.71  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 46.63 46.79 63.02 50.11
Cost of Goods Sold 11.81 13.71 11.67 13.82
Selling & Admin Exps 15.19 11.54 10.22 23.70
Operating Income 2.31 10.44 24.95 5.90
Interest Exp 0.68 0.54 0.53 0.04
Pretax Income 1.66 9.94 24.46 5.88
Other Income 0.03 0.04 0.04 0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income 2.62 9.09 15.43 4.50

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 95.67 114.66 97.55 55.39
Receivables - Total 53.43 53.82 71.60 53.23
Inventories - Total 6.14 5.12 4.88 3.59
Total Current Assets 168.82 188.70 182.15 123.87
Net Property, Plant & Equipment 6.50 6.82 4.37 3.77
Total Assets 249.30 270.06 266.89 220.18
Liabilities        
Accounts Payable 22.46 27.37 29.34 30.83
Debt in Current Liabilities 6.25 4.88 5.00 NA
Total Current Liabilities 28.76 47.30 34.40 31.95
Long-Term Debt 41.62 42.91 43.94 NA
Total Liabilities 71.12 90.92 95.81 54.82
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.02 0.02 0.02 0.02
Retained Earnings 28.90 26.28 17.20 1.77
Treasury Stock -87.80 -80.80 -75.79 -62.31
Total Stockholders' Equity 178.18 179.14 171.08 165.36
Total Liabilities and Stockholders' Equity 249.30 270.06 266.89 220.18

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities 4.92 25.92 7.89 37.55
Net Cash Provided by Investing Activities -0.02 -2.73 -1.57 -0.21
Net Cash Provided by Financing Activities -23.89 -6.08 35.85 -9.67

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201419.10-17.98-0.92
12/20145.60-5.51-0.92
12/201566.232.570.16
12/2016189.4881.454.96
12/2017236.7151.943.27
Growth Rates87.63----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/1819715,760--




Report Date : 6/11/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.